{"url_path":"/sec/fblg/8-k/2026-07-09/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-299290-index.html","accession_number":"0001193125-26-299290","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-299290-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":128,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\n \n\nA copy of the Company’s press release announcing the appointment of Dr. Rubins to the Board has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.\n\nThe information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report."}